exocrine pancreatic insufficiency (EPI)

View All

Exocrine Pancreatic Insufficiency Market Size | EPI Pipeline
What Can Help Manage The Insufficient Pancreas?

The launch of the Pipeline therapies, increasing EPI prevalence shall fuel the Exocrine pancreatic insufficiency market size estimated to be approximately USD 1,695.26 Million in 2017.  A loss of acinar pancreatic cells that causes insufficient production of pancreatic enzymes in the duodenum results in Exo...

Find More

transthyretin amyloidosis
Notizia

The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...

Find More